The Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED)

Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age30-65
SponsorUniversity of Virginia

About this trial

This is clinical trials is to evaluate the effect of exercise with weight loss medication compared to weight loss alone. The study will enroll 24 adults from 30-65 years old with overweight or obesity.

The main questions it will answer includes:

* Does exercise combined with weight loss medication reduce body weight and body fat more than weight loss medication alone * Does exercise combined with weight loss medication improve other risk factors more such as the sugar in the blood, cholesterol, fitness, and quality of life

Participants will:

* Take a weight loss medication (tirzepatide) monthly under the supervision of their primary care physician * (Exercise group only) Will perform exercise \~3 times a week at the University of Virginia). Walking on a treadmill and resistance training * Visit the study site at the beginning of the study and after the study to evaluate weight, body fat, and other health measures

Eligibility criteria

Qualifiers

Men and women 30-65 years of age, postmenopausal women included

27-29.9 with an additional CVD risk factor or 30-40 kg/m2

For overweight adults only: additional cardiometabolic risk factor (diagnosed dyslipidemia, hypertension)

Willingness and adequate health to go on weight loss medication

Disqualifiers

Including but not limited to serious arrhythmias

Cardiomyopathy

Congestive heart failure

Stroke or transient ischemic attacks

Trial design

Treatments tested in this trial

  • Tirzepatide
  • Exercise

Treatment groups

24 Participants
are divided into 2 treatment groups

Sponsors and collaborators